Exploring new methods for chemical synthesis using cobalt and organic compounds
Official title: Nucleophilic Cobalt Photocatalysis and Organic Single-Electron Photoreductants; Two Enabling Approaches for Chemical Synthesis
Funded at Oklahoma State University Stillwater · NIH-10937742 · Data updated 2026-11-12
This study is exploring new ways to create medicines by using special chemical techniques that help make important building blocks for drugs, which could lead to better treatments for health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma State University Stillwater NIH-funded |
| Lab location | 1 site (Stillwater, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $364,006 |
| NIH project number | 1R35GM154751-01 |
| Project ID | NIH-10937742 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals with conditions that could be treated by new pharmaceuticals developed through advanced chemical synthesis.
✕Less likely to help
Patients who are not seeking new treatment options or those with conditions that do not require novel pharmaceutical interventions may not benefit from this research.
What this research studies
This research focuses on developing innovative techniques in chemical synthesis through nucleophilic cobalt photocatalysis and organic single-electron photoreductants. By expanding the range of carbon radical precursors, the project aims to provide medicinal chemists with new synthetic methods that can lead to the creation of novel pharmaceuticals. The approach involves using cobaloxime complexes as catalysts to generate carbon-centered radicals from various electrophilic precursors, which could enhance the efficiency and effectiveness of organic synthesis. This work is expected to have significant implications for improving human health by facilitating the development of new medicinal compounds.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new drugs and therapies that improve patient outcomes.
How similar studies have gone: While the specific approach of using nucleophilic cobalt photocatalysis is relatively novel, similar strategies in organic synthesis have shown promising results in other research.
Where this research is happening
-
Oklahoma State University Stillwater
Stillwater, United States Active
Researchers
- Principal investigator: Pitre, Spencer — Oklahoma State University Stillwater
- Study coordinator: Pitre, Spencer
Related research
Other NIH-funded projects on the same topics.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Understanding how a calcium sensor helps Pseudomonas infections resist the immune system
This project looks at how the bacteria Pseudomonas aeruginosa uses a calcium sensor to survive and cause infections in people with conditions like cystic fibrosis.
-
ERK1/2 signaling and SARS-CoV-2 immune dysregulation in the lung
Aims to see if blocking ERK1/2 in immune cells can reduce dangerous lung inflammation from SARS-CoV-2 and boost antiviral defenses.
-
OADDL Testing Support for Vet-LIRN (Veterinary Network)
A veterinary diagnostic lab in Oklahoma will support national animal health surveillance and testing programs by handling clinical samples, animal feeds, environmental samples, and necropsies to help keep animal health and food safety safer.
-
How social life affects cognitive health in older adults in rural and urban areas
A study following older adults in rural and urban areas to see how social networks and daily activities relate to thinking skills over time.
-
Biophysical view of how enzymes work to help fight cancer
A scientist is studying how enzymes work on a deep, molecular level to help design better cancer drugs with fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.